Classifications: lung surfactant; Therapeutic: lung surfactant
Pregnancy Category: Not applicable
35 mg/mL suspension
Pulmonary surfactant. Lowers the surface tension on alveolar surfaces during respiration and stabilizes the alveoli against
collapse at resting pressure. Deficiency of surfactant causes respiratory disease syndrome (RDS) in premature infants.
Effectively relieves and prevents RDS in neonates.
Prevention and treatment of RDS in infants at high risk for RDS.
Bovine protein hypersensitivity; nosocomial infections.
Route & Dosage
|Prevention & Treatment of RDS
Infant: Intratracheal 3 mL/kg of birth weight administered through an endotracheal tube q12h x 3 doses
- Swirl vial to disperse suspension; do not dilute and DO NOT SHAKE. Withdraw with 20-gauge or larger needle. Avoid excess
foaming. Instill into the endotracheal tube, preferably within 30 min of birth.
- Stop administration of calfactant if reflux into endotracheal tube occurs as indicated by cyanosis, bradycardia, or other
signs of airway obstruction.
Adverse Effects (≥1%) CV: Bradycardia. Respiratory: Cyanosis, airway obstruction, reflux of surfactant
into endotracheal tube.
No clinically significant interactions established.
Absorbs rapidly to air; liquid interface of lung surface.
Assessment & Drug Effects
- Monitor closely during and after administration; adjustments in oxygen therapy and ventilator pressures are usually needed.
Patient & Family Education
- This drug will help baby to breathe properly and support normal respiratory function.